Question · asked by 1 review

Oral 5‐aminosalicylic acid vs 5‐aminosalicylic acid (5‐ASA) (mesalazine): Serious adverse events

Population
Patients with quiescent ulcerative colitis
Intervention
Oral 5‐aminosalicylic acid
Comparison
5‐aminosalicylic acid (5‐ASA) (mesalazine)
Outcome
Serious adverse events

Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
Oral 5‐aminosalicylic acid vs comparator 5‐aminosalicylic acid formulation
Serious adverse events · people with quiescent UC
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).
Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis (2020) · Cochrane Headline outcomes only
RR 0.56 [0.14, 2.22]1 study · 95 participantsLow

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis
2020 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed

The same intervention and outcome, asked in another population or against another comparator.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.